Skip to main content

TBG Diagnostics Value Stock - Dividend - Research Selection

TBG Diagnostics


Market price date: 30.11.-0001
Market price: 0,00 USD

TBG Diagnostics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 30-10-2015
Cash flow
Net operating cash flow -4.390.000
Capital Expenditures -1.260.000
Free cash flow -5.650.000
Balance sheet
Total Equity 23.000.000
Liabilities & Shareholders equity 25.000.000
Income statement
Net income -12.000.000
Eps (diluted) -0,065
Diluted shares outstanding 185.000.000
Net sales/revenue 3.270.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization0,00 USD
Raw Data Source
Stock Split

Description of the company

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,